NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.787
+0.144 (22.37%)
At close: Dec 24, 2024, 4:00 PM
0.804
+0.017 (2.21%)
After-hours: Dec 24, 2024, 4:43 PM EST
NKGen Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
28.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
Dec 31, 2021 | 426.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNKGN News
- 22 days ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire
- 4 weeks ago - NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - GlobeNewsWire
- 2 months ago - NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - GlobeNewsWire
- 4 months ago - NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - GlobeNewsWire